271 related articles for article (PubMed ID: 29723133)
1. Antipyrimidine effects of five different pyrimidine de novo synthesis inhibitors in three head and neck cancer cell lines.
Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2018; 37(6):329-339. PubMed ID: 29723133
[TBL] [Abstract][Full Text] [Related]
2. Effects of acivicin and PALA, singly and in combination, on de novo pyrimidine biosynthesis.
Kensler TW; Jayaram HN; Cooney DA
Adv Enzyme Regul; 1982; 20():57-73. PubMed ID: 7113804
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
Kensler TW; Mutter G; Hankerson JG; Reck LJ; Harley C; Han N; Ardalan B; Cysyk RL; Johnson RK; Jayaram HN; Cooney DA
Cancer Res; 1981 Mar; 41(3):894-904. PubMed ID: 7459875
[TBL] [Abstract][Full Text] [Related]
4. Uracil nucleotide synthesis in a human breast cancer cell line (MCF-7) and in two drug-resistant sublines that contain increased levels of enzymes of the de novo pyrimidine pathway.
Karle JM; Cowan KH; Chisena CA; Cysyk RL
Mol Pharmacol; 1986 Aug; 30(2):136-41. PubMed ID: 2874477
[TBL] [Abstract][Full Text] [Related]
5. Stable mutants of mammalian cells that overproduce the first three enzymes of pyrimidine nucleotide biosynthesis.
Kempe TD; Swyryd EA; Bruist M; Stark GR
Cell; 1976 Dec; 9(4 Pt 1):541-50. PubMed ID: 12870
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effects with inhibitors of de novo pyrimidine synthesis, acivicin, and N-(phosphonacetyl)-L-aspartic acid.
Loh E; Kufe DW
Cancer Res; 1981 Sep; 41(9 Pt 1):3419-23. PubMed ID: 7260907
[TBL] [Abstract][Full Text] [Related]
7. N-(Phosphonacetyl)-L-aspartate inhibition of the enzyme complex of pyrimidine biosynthesis.
Moore EC
Biochem Pharmacol; 1982 Oct; 31(20):3313-6. PubMed ID: 7150357
[TBL] [Abstract][Full Text] [Related]
8. Re-evaluation of Brequinar sodium, a dihydroorotate dehydrogenase inhibitor.
Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2018; 37(12):666-678. PubMed ID: 30663496
[TBL] [Abstract][Full Text] [Related]
9. DUP 785 (NSC 368390): schedule-dependency of growth-inhibitory and antipyrimidine effects.
Schwartsmann G; Peters GJ; Laurensse E; de Waal FC; Loonen AH; Leyva A; Pinedo HM
Biochem Pharmacol; 1988 Sep; 37(17):3257-66. PubMed ID: 2840910
[TBL] [Abstract][Full Text] [Related]
10. Effect of high-protein diet on pyrimidine synthesis and response to PALA in mouse tissues.
Zaharevitz DW; Grubb MF; Hyman R; Chisena C; Cysyk RL
J Natl Cancer Inst; 1993 Apr; 85(8):662-6. PubMed ID: 8468725
[TBL] [Abstract][Full Text] [Related]
11. Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate.
Moore EC; Friedman J; Valdivieso M; Plunkett W; Marti JR; Russ J; Loo TL
Biochem Pharmacol; 1982 Oct; 31(20):3317-21. PubMed ID: 7150358
[TBL] [Abstract][Full Text] [Related]
12. Uridylate-trapping sugar analogs in combination with inhibitors of uridylate synthesis de novo and 5-fluorouridine.
Keppler D; Fauler J; Gasser T; Holstege A; Leube K; Schulz-Holstege C; Weckbecker G
Adv Enzyme Regul; 1985; 23():61-79. PubMed ID: 2416194
[TBL] [Abstract][Full Text] [Related]
13. Combined action of acivicin and D-galactosamine on pyrimidine nucleotide metabolism in hepatoma cells.
Leube K; Keppler DO
Biochem Pharmacol; 1983 Jun; 32(12):1865-9. PubMed ID: 6882463
[TBL] [Abstract][Full Text] [Related]
14. Flux through the de novo pyrimidine pathway in vivo. Effect of N-phosphonacetyl-L-aspartate, a potent inhibitor of aspartate transcarbamylase.
Monks A; Anderson LW; Strong J; Cysyk RL
J Biol Chem; 1983 Nov; 258(22):13564-9. PubMed ID: 6417130
[TBL] [Abstract][Full Text] [Related]
15. Rapid in vivo inactivation by acivicin of CTP synthetase, carbamoyl-phosphate synthetase II, and amidophosphoribosyltransferase in hepatoma.
Denton JE; Lui MS; Aoki T; Sebolt J; Weber G
Life Sci; 1982 Mar; 30(13):1073-80. PubMed ID: 7078346
[TBL] [Abstract][Full Text] [Related]
16. Retention of in vivo antipyrimidine effects of Brequinar sodium (DUP-785; NSC 368390) in murine liver, bone marrow and colon cancer.
Peters GJ; Nadal JC; Laurensse EJ; de Kant E; Pinedo HM
Biochem Pharmacol; 1990 Jan; 39(1):135-44. PubMed ID: 2153375
[TBL] [Abstract][Full Text] [Related]
17. Site of action of two novel pyrimidine biosynthesis inhibitors accurately predicted by the compare program.
Cleaveland ES; Monks A; Vaigro-Wolff A; Zaharevitz DW; Paull K; Ardalan K; Cooney DA; Ford H
Biochem Pharmacol; 1995 Mar; 49(7):947-54. PubMed ID: 7741767
[TBL] [Abstract][Full Text] [Related]
18. Effects of acivicin and dichloroallyl lawsone upon pyrimidine biosynthesis in mouse L1210 leukemia cells.
Kemp AJ; Lyons SD; Christopherson RI
J Biol Chem; 1986 Nov; 261(32):14891-5. PubMed ID: 3771555
[TBL] [Abstract][Full Text] [Related]
19. PALA enhancement of bromodeoxyuridine incorporation into DNA increases radiation cytotoxicity to human ovarian adenocarcinoma cells.
Yang JL; Fernandes DJ; Wheeler KT; Capizzi RL
Int J Radiat Oncol Biol Phys; 1996 Mar; 34(5):1073-9. PubMed ID: 8600090
[TBL] [Abstract][Full Text] [Related]
20. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
Ardalan B; Jayaram HN; Johnson RK
Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
